Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 4.90

From 52W high−30.59%

Volume36.90M

Market capCNY 31.71B

P/E (TTM)20.1x

P/S (TTM)4.7x

Div yield0.98%

Key dataSep 18, 2026

Open

CNY 4.90

From 52W high

−30.59%

Volume

36.90M

Market cap

CNY 31.71B

ValuationView details →

P/E (Fwd)

27.4x

EV/EBITDA

16.0x

P/E (TTM)

20.1x

RSI (14)

49.4

MomentumView details →

1D Return

−0.21%

YTD Return

−22.24%

ValuationView details →

P/E (Fwd)

27.4x

P/E (TTM)

20.1x

EV/EBITDA

16.0x

EV/Sales

5.0x

P/S (TTM)

4.7x

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

37.00%

Net Margin

19.36%

EBITDA Margin

31.40%

ROE (TTM)

4.08%

ROA (TTM)

3.49%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

−15.68%

EPS YoY

−33.47%

FCF YoY

−69.31%

Revenue CAGR 3Y

+3.82%

EPS CAGR 3Y

−5.01%

EBITDA YoY

—

MomentumView details →

1D Return

−0.21%

YTD Return

−22.24%

1Y Return

−27.18%

RSI (14)

49.4

vs 50D SMA

−1.23%

vs 200D SMA

−12.19%

Capital & dividendView details →

Debt/Equity

0.12x

Current Ratio

3.73x

Quick Ratio

1.74x

Div Yield

0.98%

Div Rate

CNY 0.05

Div Growth 1Y

+46.36%

EarningsView details →

EPS (Actual)

CNY 0.05

EPS Surprise

−41.14%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.10

Avg Surprise (4Q)

−41.14%

Rev Surprise

−27.07%

Financials snapshotView financials →

Revenue (TTM)

6.85B

Net Income (TTM)

1.33B

Op. CF (TTM)

−943.68M

Next earningsOct 23, 2026 →

Latest newsMore news →

Shanghai RAAS Blood Products' wholly-owned subsidiary Nanyue Biopharmaceutical received a drug registration certificate from the National Medical Products Administration for human fibrinogen injection (0.5g/vial) for congenital fibrinogen deficiency or absence.2d ago

Shanghai RAAS Blood Products announced that its investigational SR604 injection entered Phase III clinical trials for hemophilia A/B after its Phase I/II study met the primary endpoint, with the trial registered as CTR20263539 on China's drug clinical trial registration platform.4d ago

Similar companies

斯迪克300806.SZ 英科医疗300677.SZ 九安医疗002432.SZ 燕京啤酒000729.SZ 蓝晓科技300487.SZ 鹏辉能源300438.SZ Find similar companies →

Latest newsMore news →

Shanghai RAAS Blood Products' wholly-owned subsidiary Nanyue Biopharmaceutical received a drug registration certificate from the National Medical Products Administration for human fibrinogen injection (0.5g/vial) for congenital fibrinogen deficiency or absence.2d ago Shanghai RAAS Blood Products announced that its investigational SR604 injection entered Phase III clinical trials for hemophilia A/B after its Phase I/II study met the primary endpoint, with the trial registered as CTR20263539 on China's drug clinical trial registration platform.4d ago Shanghai RAAS announced a share buyback plan of 250 million to 500 million yuan to cancel shares and reduce registered capital.11d ago